SAFETY DATA SHEET

Version 5.1 Revision Date 10/12/2018
Print Date 09/30/2019

Avanti Polar Lipids, Inc. 700 Industrial Park Drive, Alabaster, AL 35007,USA • (800) 227-0651 • (205) 663-2494
• Fax(800) 229-1004•(205) 663-0756 • E-mail Orders: orders@avantilipids.com • E-mail Inquiries: info@avantilipids.com
• E-mail Technical Questions: technical@avantilipids.com • Visit www.avantilipids.com

1. PRODUCT AND COMPANY IDENTIFICATION

1.1 Product identifiers

Product name : Dox-NP® (2mL vial)

Product Number : 300112S
Brand : AVANTI

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Laboratory chemicals, Synthesis of substances

1.3 Details of the supplier of the safety data sheet

Company : Avanti Polar Lipids, INC
700 Industrial Park Drive
Alabaster, Al 35007
United States of America

Telephone : (205) 663-2494
Fax : (205) 663-0756

1.4 Emergency telephone number

Emergency Phone # : +1 703-741-5970 / 1800-424-9300(CHEMTREC)

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
Germ cell mutagenicity (Category 1B), H340
Carcinogenicity (Category 1B), H350
Reproductive toxicity (Category 1B), H360

For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2 GHS Label elements, including precautionary statements

Pictogram

Signal word Danger

Hazard statement(s)

H340	May cause genetic defects.
H350	May cause cancer.
H360	May damage fertility or the unborn child.

Precautionary statement(s)

P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P280	Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P313	IF exposed or concerned: Get medical advice/ attention.

P405	Store locked up.
P501	Dispose of contents/ container to an approved waste disposal plant.

2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.2 Mixtures

Hazardous components

Component		Classification	Concentration
Sucrose			
CAS-No. EC-No.	57-50-1 200-334-9		10 - 20 %
Doxorubicin hydrochloride			
CAS-No. EC-No.	25316-40-9 246-818-3	Acute Tox. 4; Muta. 1B; Carc. 1B; Repr. 1B; H302, H340, H350, H360	0.1 - 1 %

For the full text of the H-Statements mentioned in this Section, see Section 16.

4. FIRST AID MEASURES

4.1 Description of first aid measures

General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.

If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

In case of skin contact
Wash off with soap and plenty of water. Consult a physician.

In case of eye contact
Flush eyes with water as a precaution.

If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3 Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES

5.1 Extinguishing media

Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2 Special hazards arising from the substance or mixture
No data available

5.3 Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4 Further information
No data available

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.
For personal protection see section 8.

6.2 Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

6.3 Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed containers for disposal.

6.4 Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling
Avoid inhalation of vapour or mist.
For precautions see section 2.2.

7.2 Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed and kept upright to prevent leakage.

Recommended storage temperature -20 °C
Storage class (TRGS 510): 6.1D: Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

7.3 Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components with workplace control parameters

Component	CAS-No.	Value	Control parameters	Basis
Sucrose	57-50-1	TWA	10 mg/m3	USA. ACGIH Threshold Limit Values (TLV)
	Remarks	Dental erosion Not classifiable as a human carcinogen		
		TWA	10.000000 mg/m3	USA. ACGIH Threshold Limit Values (TLV)
		Dental erosion Not classifiable as a human carcinogen		

		TWA	15.000000 mg/m3	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
		TWA	5.000000 mg/m3	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
		TWA	5.000000 mg/m3	USA. NIOSH Recommended Exposure Limits
		TWA	10.000000 mg/m3	USA. NIOSH Recommended Exposure Limits
		PEL	10 mg/m3	California permissible exposure limits for chemical contaminants (Title 8, Article 107)
		PEL	5 mg/m3	California permissible exposure limits for chemical contaminants (Title 8, Article 107)

Hazardous components without workplace control parameters

8.2 Exposure controls

Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

Personal protective equipment

Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

a)	Appearance	Form: liquid
b)	Odour	No data available
c)	Odour Threshold	No data available
d)	pH	No data available
e)	Melting point/freezing point	No data available
f)	Initial boiling point and boiling range	No data available
g)	Flash point	No data available
h)	Evaporation rate	No data available

i)	Flammability (solid, gas)	No data available
j)	Upper/lower flammability or explosive limits	No data available
k)	Vapour pressure	No data available
l)	Vapour density	No data available
m)	Relative density	No data available
n)	Water solubility	No data available
o)	Partition coefficient: n-octanol/water	No data available
p)	Auto-ignition temperature	No data available
q)	Decomposition temperature	No data available
r)	Viscosity	No data available
s)	Explosive properties	No data available
t)	Oxidizing properties	No data available

9.2 Other safety information
No data available

10. STABILITY AND REACTIVITY

10.1 Reactivity
No data available

10.2 Chemical stability
Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions
No data available

10.4 Conditions to avoid
No data available

10.5 Incompatible materials
Strong oxidizing agents

10.6 Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity
No data available

Inhalation: No data available

Dermal: No data available

No data available

Skin corrosion/irritation
No data available

Serious eye damage/eye irritation
No data available

Respiratory or skin sensitisation
No data available

Germ cell mutagenicity
No data available

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

NTP: RAHC - Reasonably anticipated to be a human carcinogen (Doxorubicin hydrochloride)

OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

Reproductive toxicity
No data available
No data available

Specific target organ toxicity - single exposure
No data available

Specific target organ toxicity - repeated exposure
No data available

Aspiration hazard
No data available

Additional Information
RTECS: Not available

To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

Liver - Irregularities - Based on Human Evidence
Liver - Irregularities - Based on Human Evidence (Doxorubicin hydrochloride)

12. ECOLOGICAL INFORMATION

12.1 Toxicity
No data available

12.2 Persistence and degradability
No data available

12.3 Bioaccumulative potential
No data available

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6 Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.

Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION

DOT (US)
Not dangerous goods

IMDG
Not dangerous goods

IATA
Not dangerous goods

15. REGULATORY INFORMATION

SARA 302 Components
This material does not contain any components with a section 302 EHS TPQ.

SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards
Chronic Health Hazard

Massachusetts Right To Know Components

	CAS-No.	Revision Date
Sucrose	57-50-1	1991-07-01

Pennsylvania Right To Know Components

	CAS-No.	Revision Date
Water	7732-18-5	
Sucrose	57-50-1	1991-07-01
Doxorubicin hydrochloride	25316-40-9	2014-10-14
Ammonium sulphate	7783-20-2	1993-04-24

California Prop. 65 Components

, which is/are known to the State of California to cause cancer and birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.	CAS-No.	Revision Date
Doxorubicin hydrochloride	25316-40-9	2008-06-17

16. OTHER INFORMATION

Full text of H-Statements referred to under sections 2 and 3.

Acute Tox.	Acute toxicity
Carc.	Carcinogenicity
H302	Harmful if swallowed.
H340	May cause genetic defects.
H350	May cause cancer.
H360	May damage fertility or the unborn child.
Muta.	Germ cell mutagenicity
Repr.	Reproductive toxicity

Further information

The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956

Version: 5.1 Revision Date: 10/12/2018 Print Date: 09/30/2019